Ilsung Is Co., Ltd. (003120.KS) Stock
Ilsung Is Co., Ltd.

Company profile
Ilsung Is reported revenue of 64.29 billion KRW for fiscal year 2025, down 6.8% from fiscal year 2024, and net income of 1.17 billion KRW. That is a net profit margin of 1.8% for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 78.05 billion KRW in fiscal year 2023 to 64.29 billion KRW in fiscal year 2025, 9.2% a year on average.
What stands out
- Net income fell 91.1% in fiscal year 2025, from 13.09 billion KRW in fiscal year 2024.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Ilsung Is Co., Ltd.
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
Largest shareholders
- Ilsung Is Co., Ltd.46.15%
- Suk-Keun Yoon20.88 %20.88%
- Hyung-jin Yoon8.026 %8.03%
- Daejung Scholarship Foundation4.22%
- Duk-Keun Yoon4.15 %4.15%
Share of the company, as of September 25, 2026
Leadership
- Seok-geun Yoon — Chairman & CEO, 69
How much revenue does Ilsung Is make?
Ilsung Is reported 64.29 billion KRW in revenue for fiscal year 2025, down 6.8% from 69.02 billion KRW in fiscal year 2024.
What companies are similar to Ilsung Is?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include DAE HWA Pharmaceutical Co., Ltd. (067080.KQ), Samil Pharmaceutical Co.,Ltd (000520.KS), Yungjin Pharm. Co., Ltd. (003520.KS), Hana Pharm Co., Ltd. (293480.KS).
Has Ilsung Is made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 1.37 billion KRW; FY2022, 108.67 billion KRW; FY2023, a loss of 20.94 billion KRW; FY2024, 13.09 billion KRW; FY2025, 1.17 billion KRW. It reported a net loss in 2 of these 5 years.
Data as of .
How to cite: DataPorium, “Ilsung Is Co., Ltd. (003120.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003120.KS